A Phase 2/3 interventional study of Epetraborole and Placebo in MAC Lung Disease and Treatment Refractory MAC Lung Disease, sponsored by AN2 Therapeutics, Inc. Terminated at 91 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.
Sponsored by AN2 Therapeutics, Inc · Phase 2/3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 210 studies in Respiratory Tract Infections with a site in United States — 21 open to participants now, 28 under way, 5 of them phase 3. Respiratory Tract Infections · United States.
Among the 210 studies in Respiratory Tract Infections with a site in United States, this one is the 72nd largest by enrollment of the 160 interventional ones that give a count, is one of 11 that started in 2022, is one of 2 in phase 2/3, and was the 163rd registered.
753 studies on the registry are indexed under Respiratory Tract Infections; 114 are open to participants now.
Browse Respiratory Tract Infections studies →21 of the 210 studies in Respiratory Tract Infections with a site in United States are open now. Recruiting first, the newest first:
University of Minnesota · Sites in United States
Ages 7–17 · Healthy volunteers
National Institute on Deafness and Other Communication Disorders (NIDCD) · Sites in United States
Ages 18–99 · Healthy volunteers
BioNTech SE · Sites in United States
Ages 5+ · Healthy volunteers
BioNTech SE · Sites in United States
Ages 18–64 · Healthy volunteers
University Hospital, Grenoble · Sites in United States, France, Germany and 2 more countries
Ages 60+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 74 Respiratory Tract Infections studies recruiting now, 35 (47%) set no upper age limit and 31 (42%) stop at 75 or younger; 34 take children under 18; 25 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
210 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 29 · Phase 2 42 · Phase 3 22 · Phase 4 14
First in 1997; this study’s year is marked. 11 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 177 is below the median of 200 across 542 interventional studies indexed under Respiratory Tract Infections.
Median enrollment 137 across the 160 interventional studies, 558 across the 48 observational. Of the 172 that completed or were terminated, 67 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
85 of 210 have an industry lead sponsor. The 10 most frequent:
AN2 Therapeutics, Inc is the lead sponsor of 7 studies on the registry; 1 is open to participants now.
AN2 Therapeutics, Inc has 1 study filed under Respiratory Tract Infections — fewer than ten, so there is no comparison to draw.
14 of the studies in Respiratory Tract Infections with a site in United States that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07798648Phase 3BioNTech SEA Study of COVID-19 Vaccine(s) in Children and Adults | 2027-04-21 |
| NCT07013474Phase 3PfizerA Study to Learn About the Study Medicine Ibuzatrelvir in Adults With COVID-19 Who Are Severely Immunocompromised | 2027-09-28 |
| NCT06679140Phase 3PfizerA Study to Learn About a Study Medicine Called Ibuzatrelvir in Adult and Adolescent Patients With COVID-19 Who Are Not Hospitalized But Are at Risk For Severe Disease | 2027-10-01 |
| NCT05624450Phase 3AstraZenecaEfficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen | 2027-11-04 |
| NCT05474430Philip PolgreenEstimating Risk of Respiratory Infections Attributable to CFTR Heterozygosity | 2026-12 |
Add all 14 to your calendar (.ics) → With an account.
Among the 210 studies in Respiratory Tract Infections with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a pivotal Phase 2/3, double-blind, placebo-controlled study of epetraborole + OBR (Optimized Background Regimen) versus placebo + OBR in patients with treatment-refractory MAC lung disease. This study will enroll adult patients with treatment-refractory MAC lung disease who meet all eligibility criteria (including clinical, radiographic, and microbiological criteria).
In the Phase 2 part of the study, approximately 80 patients will be randomized in a 1:1 ratio (40 patients receiving active epetraborole tablets and 40 patients receiving matching placebo tablets). The Phase 2 part of the study includes a blinded psychometric analysis plan to assess the psychometric properties of a novel PRO instrument. In addition, symptom-based clinical responses will be assessed using blinded data, to inform the measurement of clinical response in the Phase 3 part of the study.
The Phase 3 part of the study will test the superiority of epetraborole + OBR compared to placebo + OBR. In this part of the study, approximately 234 patients are planned to be randomized in a 2:1 ratio (156 patients receiving active epetraborole tablets and 78 patients receiving matching placebo tablets). The current symptom-based clinical response definition (using the novel PRO) in Phase 3 is a placeholder to be verified after Phase 2 analyses based on data through Month 6. In addition, the Sponsor will determine if the sample size for Phase 3 should be adjusted and will verify the Phase 3 epetraborole dosage regimen based on the observed plasma epetraborole exposure.
Phase 3 data analyses will include a review of patient-reported outcomes, microbiological, safety, and PK data collected at multiple time points through Month 6. Patients in Phase 3 will continue double-blinded study drug for 12 months after the first negative MAC culture that defines sputum culture conversion; study drug will be discontinued in patients who remain MAC culture positive despite 6 months of therapy with study drug.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with a diagnosis of treatment- MAC lung disease consisting of all of the following (a) Microbiological, (b) Clinical, and (c) Radiographic criteria:
Microbiological criteria:
Clinical criteria: At least 2 of the following patient-reported clinical symptoms:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
epetraborole + Optimized Background Regimen
Drug: Epetraborole
Placebo + Optimized Background Regimen
Drug: Placebo
500 mg taken orally QD
Also known as: AN2-501971
Placebo taken orally QD
Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole
Percentage of Participants reporting treatment emergent adverse events
Time frame: Baseline to Month 16
Phase 2: Percentage of Participants Achieving Clinical Response
Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)
Time frame: Baseline to Month 6
Phase 3: Percentage of Participants Achieving Clinical Response
Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)
Time frame: Baseline to Month 6
Phase 2: Percentage of Participants Achieving Culture Conversion
Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.
Time frame: Baseline to Month 6
Phase 2: Percentage of Participants Achieving Microbiological Improvement
Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.
Time frame: Baseline to Month 6
Phase 2: Change From Baseline in QOL-B Respiratory Domain PRO
Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 2: Change From Baseline in NTM Symptoms Module PRO
Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 2: Change From Baseline in SGRQ-C PRO
Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 2: Concordance Analysis of PRO-based Clinical Response and Microbiological Response
Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement.
Time frame: Baseline to Month 6
Phase 2: Maximum Plasma Concentration (Cmax) of Epetraborole
Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.
Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported
Phase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose
AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.
Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 1 Result Reported
Phase 2: Volume of Distribution (Vd) of Epetraborole
Vd is the apparent volume of distribution of epetraborole estimated by population PK model.
Time frame: Day 1 (2-3 hours post-dose) and Day 29 (within 1 hour pre-dose and 2-3 hours post-dose); Day 29 Result Reported
Phase 3: Percentage of Participants Achieving Culture Conversion
Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.
Time frame: Baseline to Month 6
Phase 3: Percentage of Participants Achieving Microbiological Improvement
Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.
Time frame: Baseline to Month 6
Phase 3: Change From Baseline in QOL-B Respiratory Domain PRO
Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 3: Change From Baseline in NTM Symptoms Module PRO
Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 3: Change From Baseline in SGRQ-C PRO
Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).
Time frame: Measured at Baseline and months 1, 2, 3, 4, 5, and 6; Change from Baseline to Month 6 Reported
Phase 3: Concordance Analysis of PRO-based Clinical Response and Microbiological Response
Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement
Time frame: Baseline to Month 6
Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole
Percentage of Participants reporting treatment emergent adverse events.
Time frame: Baseline to Month 16
This study included 2 phases of enrollment. 80 participants in Phase 2 were randomized 1:1 to Epetraborole or Placebo arms, both including Optimized Background Regimen (OBR) 97 participants in Phase 3 were randomized 2:1 to Epetraborole or Placebo arms, both including Optimized Background Regimen (OBR)
| Milestone | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Started | 39 | 41 |
| Completed | 35 | 34 |
| Not completed | 4 | 7 |
| Milestone | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Started | 66 | 31 |
| Completed | 52 | 22 |
| Not completed | 14 | 9 |
Percentage of Participants reporting treatment emergent adverse events
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole | 37 | 35 |
Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Percentage of Participants Achieving Clinical Response | 15 | 10 |
Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Percentage of Participants Achieving Culture Conversion | 5 | 4 |
Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Percentage of Participants Achieving Microbiological Improvement | 9 | 16 |
Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).
| Change from baseline score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Change From Baseline in QOL-B Respiratory Domain PRO | 7.20 ± 2.447 | 0.30 ± 2.569 |
Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).
| Change from baseline score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Change From Baseline in NTM Symptoms Module PRO | 6.20 ± 2.599 | 0.83 ± 2.746 |
Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).
| Change from baseline score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Change From Baseline in SGRQ-C PRO | -2.27 ± 2.317 | 0.33 ± 2.464 |
Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| PRO responder and culture conversion | 2 | 1 |
| PRO responder and no culture conversion | 13 | 9 |
| PRO failure and culture conversion | 3 | 3 |
| PRO failure and no culture conversion | 20 | 27 |
Cmax is the maximum plasma concentration of epetraborole estimated by population PK model.
| ug/mL | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Maximum Plasma Concentration (Cmax) of Epetraborole | 2.73 ± 18.9 | — |
AUC(0-24) is defined as area under the plasma concentration-time curve of epetraborole from timepoint 0 hours until 24 hours post dose estimated by population PK model.
| ug*hr/mL | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Area Under the Plasma Concentration-Time Curve From Time Point 0 Hours Until 24 Hours [AUC(0-24)] Post Dose | 14.8 ± 19.8 | — |
Vd is the apparent volume of distribution of epetraborole estimated by population PK model.
| L | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 2: Volume of Distribution (Vd) of Epetraborole | 174 ± 16.2 | — |
Sputum conversion will be assessed using culture conversion based on 3 consecutive monthly negative sputum cultures for MAC by Month 6.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Percentage of Participants Achieving Culture Conversion | 5 | 3 |
Microbiological improvement will be assessed at Month 3 and Month 6 using decrease in MAC colony counts of ≥1 category.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Percentage of Participants Achieving Microbiological Improvement | 20 | 7 |
Mean change from baseline in Quality of Life - Bronchiectasis (QOL-B) respiratory domain score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). QOL-B respiratory domain score is measured on a scale from 0 to 100 (with higher scores indicating better health-related quality of life).
| Change from baseline score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Change From Baseline in QOL-B Respiratory Domain PRO | 5.14 ± 2.252 | 4.16 ± 2.748 |
Mean change from baseline in NTM Symptoms Module PRO measured monthly through Month 6 (Change from Baseline to Month 6 Reported). NTM Symptoms Module score is measured on a scale from 0 to 100 (with higher scores indicating better function).
| Change from baseline score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Change From Baseline in NTM Symptoms Module PRO | 3.55 ± 2.477 | 1.66 ± 3.032 |
Mean change from baseline in Saint George's Respiratory Questionnaire for COPD Patients (SGRQ-C) total score measured monthly through Month 6 (Change from Baseline to Month 6 Reported). SGRQ-C total score is measured on a scale from 0 to 100 (with lower scores representing better quality of life).
| Change from baseline total score | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Change From Baseline in SGRQ-C PRO | -2.49 ± 1.873 | -3.36 ± 2.308 |
Concordance between clinical response in a novel Patient-Reported Outcome (PRO) instrument and microbiological response will be assessed at Months 3 and 6. Microbiological response will be assessed using both sputum culture conversion and microbiological improvement
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Clinical Response and Culture Conversion | 1 | 1 |
| Clinical Response and No Culture Conversion | 20 | 9 |
| Clinical Failure and Culture Conversion | 4 | 2 |
| Clinical Failure and No Culture Conversion | 40 | 19 |
Percentage of Participants reporting treatment emergent adverse events.
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Adverse Event Profile of 500 mg Once Daily Dose of Epetraborole | 59 | 23 |
Detection of within-patient changes in symptoms reported in a novel Patient-Reported Outcome (PRO) instrument at Month 6 (Clinical Response measured as improvement in at least one symptom and no worsening in any others from baseline)
| Participants | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Phase 3: Percentage of Participants Achieving Clinical Response | 21 | 10 |
Collected over Baseline to Month 16. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epetraborole + OBR | 4/105 (3.8%) | 15/105 (14.3%) | 67/105 (63.8%) |
| Placebo + OBR | 0/72 (0%) | 13/72 (18.1%) | 31/72 (43.1%) |
| Event | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| Atypical mycobacterial infectionInfections and infestations | 3/105 | 3/72 |
| PneumoniaInfections and infestations | 1/105 | 3/72 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 2/105 | 0/72 |
| Infective exacerbation of bronchiectasisInfections and infestations | 2/105 | 0/72 |
| Aortic stenosisVascular disorders | 0/105 | 1/72 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/105 | 1/72 |
| DehydrationMetabolism and nutrition disorders | 0/105 | 1/72 |
| Device breakageProduct Issues | 0/105 | 1/72 |
| HaemoptysisRespiratory, thoracic and mediastinal disorders | 1/105 | 1/72 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/105 | 1/72 |
| Event | Epetraborole + OBR | Placebo + OBR |
|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 30/105 | 1/72 |
| HeadacheNervous system disorders | 10/105 | 11/72 |
| Haemoglobin decreasedInvestigations | 12/105 | 0/72 |
| NasopharyngitisInfections and infestations | 7/105 | 8/72 |
| DizzinessNervous system disorders | 11/105 | 1/72 |
| COVID -19Infections and infestations | 9/105 | 7/72 |
| NauseaGastrointestinal disorders | 10/105 | 3/72 |
| DiarrhoeaGastrointestinal disorders | 6/105 | 3/72 |
| Age, Categorical(Participants) | Phase 2 : Epetraborole + OBR | Phase 2 : Placebo + OBR | Phase 3 : Epetraborole + OBR | Phase 3 : Placebo + OBR | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 21 | 13 | 70 |
| >=65 years | 21 | 23 | 45 | 18 | 107 |
| Sex: Female, Male(Participants) | Phase 2 : Epetraborole + OBR | Phase 2 : Placebo + OBR | Phase 3 : Epetraborole + OBR | Phase 3 : Placebo + OBR | Total |
|---|---|---|---|---|---|
| Female | 27 | 30 | 49 | 22 | 128 |
| Male | 12 | 11 | 17 | 9 | 49 |
| Race (NIH/OMB)(Participants) | Phase 2 : Epetraborole + OBR | Phase 2 : Placebo + OBR | Phase 3 : Epetraborole + OBR | Phase 3 : Placebo + OBR | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 26 | 25 | 39 | 23 | 113 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 2 | 0 | 3 |
| White | 13 | 15 | 23 | 8 | 59 |
| More than one race | 0 | 0 | 2 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | Phase 2 : Epetraborole + OBR | Phase 2 : Placebo + OBR | Phase 3 : Epetraborole + OBR | Phase 3 : Placebo + OBR | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 0 | 2 | 1 | 4 |
| Not Hispanic or Latino | 38 | 41 | 64 | 30 | 173 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Phase 2 : Epetraborole + OBR | Phase 2 : Placebo + OBR | Phase 3 : Epetraborole + OBR | Phase 3 : Placebo + OBR | Total |
|---|---|---|---|---|---|
| United States | 11 | 15 | 26 | 7 | 59 |
| Australia | 2 | 1 | 2 | 1 | 6 |
| Japan | 18 | 14 | 31 | 17 | 80 |
| South Korea | 8 | 11 | 7 | 6 | 32 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from May 2022 to primary completion in Dec 2024, 30 months.
Results were first posted in Jun 2026, 1 year 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epetraborole
Respiratory Tract Infections →
AN2 Therapeutics, Inc